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Previous reports on hepatic hydrothorax have used
different definitions of successful pleurodesis. Radiologic
evidence of recurrence is frequently observed within 2
months, even after VATS pleurodesis.3,5 Our patient is the
first reported to undergo OK-432 pleurodesis that resulted
in a 5-year remission. The second pleurodesis with OK-
432 was once again successful in terms of dramatic resolu-
tion of the recurrent hepatic hydrothorax after failure of
repeated minocycline pleurodesis.
In conclusion, patients with end-stage liver cirrhosis and
refractory hepatic hydrothorax have few therapeutic options.
Our case demonstrates that OK-432 pleurodesis through
a pigtail catheter is safe and can provide an effective alterna-
tive for patients for whom surgical intervention is not
suitable.
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Brief CommunicationsPerioperative nesiritide and possible renal protection in patients with
moderate to severe kidney dysfunction
Cornelius McKown Dyke, MD,a Devinder Bhatia, MD,b Solomon Aronson, MD,c Nader Moazami, MD,d and Robert M. Mentzer,
Jr, MD,e Gastonia, NC, Houston, Tex, Durham, NC, St Louis, Mo, and Detroit, MichPostoperative renal dysfunction develops in approximately
5% to 30% of patients undergoing cardiac surgery with
cardiopulmonary bypass, is a potent predictor of poor
outcomes, and is especially prevalent among patients with
preexisting renal dysfunction.1,2 Strategies to protect kidney
function during cardiac surgery have included the use of
low-dose dopamine, fenoldopam mesylate (INN fenoldo-
pam), bicarbonate infusion, and diuretics, yet efficacy of
any treatment has been difficult to demonstrate.
Nesiritide, a recombinant form of human B-type natri-
uretic peptide, has been suggested to be renally protective
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doi:10.1016/j.jtcvs.2007.12.079The Journal of Thoracic and Cafor patients with end-stage heart failure.3 Additionally, in
the exploratory Nesiritide Administered Peri-Anesthesia
(NAPA) trial, patients with congestive heart failure undergo-
ing cardiac surgery who received nesiritide had a signifi-
cantly lower incidence of postoperative renal dysfunction.4
The goal of this post hoc evaluation of the NAPA trial was
to assess the impact of perioperative nesiritide on patients
with preexisting, non–hemodialysis dependent, moderate-
to-severe renal dysfunction.
MATERIALS AND METHODS
The design and methodology of the NAPA trial has been reported pre-
viously.4 In brief, patients with chronic left ventricular dysfunction under-
went cardiac surgery utilizing cardiopulmonary bypass. Patients were
randomly assigned to treatment with intravenous infusion of nesiritide
(0.01 mg/[kg $ min] without bolus) or placebo in addition to usual care.
Study drug infusion was initiated after induction of anesthesia and contin-
ued for 24 to 96 hours after surgery. Inotropes and vasopressor medications
were used without restriction in accordance with institutional practice. In
the NAPA trial, 303 patients were randomly assigned, of whom 272
(nesiritide n ¼ 137, placebo n ¼ 135) ultimately underwent surgery. Of
these 272 patients, 266 (nesiritide n¼ 133, placebo n¼ 133) had a baseline
serum creatinine measurement and at least one postoperative serum creati-
nine measurement, and these patients form the basis for this evaluation.rdiovascular Surgery c Volume 136, Number 5 1369
Brief CommunicationsPreexisting renal dysfunction was defined on the basis of the estimated
glomerular filtration rate (GFR), as calculated by the Modification of
Diet in Renal Disease trial equation. The impacts of nesiritide infusion
on patients with moderate-to-severe renal dysfunction (estimated GFR 60
mL/min) and mild-to-no renal dysfunction (estimated GFR 60 mL/min)
were assessed.
Because no standard definition for postoperative renal dysfunction ex-
ists, we quantified renal dysfunction after surgery in two ways, as a greater
than 0.5-mg/dL increase in serum creatinine or as a greater than 25% de-
crease in GFR through hospital discharge or study day 14. The prevalences
of postoperative renal dysfunction in the two treatment groups were com-
pared with the Fisher exact test. The relative risk reduction was analyzed,
and the corresponding 95% confidence intervals and P values were based
on Mantel–Haenszel statistics with SAS 8.2 software (SAS Institute, Inc,
Cary, NC). Unless otherwise noted, summary statistics for continuous vari-
ables are presented as mean  SD.
RESULTS
Patient characteristics and procedures performed have
been previously detailed.4 Most patients underwent isolated
coronary artery bypass grafting. Mean left ventricular ejec-
tion fraction at baseline was 30% 7%. The mean duration
of study drug infusion was similar between groups (nesiri-
tide 39  22 hours, placebo 41  23 hours). Adjunct
pharmacologic therapy was also similar between groups.4
The incidence of postoperative renal dysfunction was
significantly reduced for all patients who received nesiri-
tide, but this protective effect was especially evident in
looking at the patients with preexisting moderate-to-severe
renal dysfunction (Figure 1). Perioperative administration
of nesiritide reduced the risk of an acute postoperative in-
crease in serum creatinine of more than 0.5 mg/dL or an
acute postoperative decrease in GRF of more than 25%
of baseline by 90% (95% confidence interval 33%–
FIGURE 1. Postoperative renal dysfunction was significantly reduced
among patients who received nesiritide, with protective effect especially ev-
ident in patients with preexisting moderate-to-severe renal dysfunction.
GFR, Glomerular filtration rate; SCr, serum creatinine.1370 The Journal of Thoracic and Cardiovascular Su99%, P ¼ .001) in patients with moderate-to-severe preex-
isting renal dysfunction.
DISCUSSION
The NAPA study was a phase 2 exploratory study that en-
rolled patients with left ventricular dysfunction undergoing
on-pump coronary bypass grafting with or without mitral
valve surgery. Nesiritide was associated with attenuation
of the increases in postoperative serum creatinine observed
in the control group. Whether nesiritide was associated
with renal protection in patients with preexisting renal dys-
function was less clear. In the previous NAPA report, preex-
isting renal dysfunction was prospectively defined as
a baseline serum creatinine greater than 1.2 mg/dL.4 The
use of serum creatinine as a definition of renal dysfunction
is questionable, however, because other factors influence se-
rum creatinine levels, including creatinine generation and
secretion. In this reanalysis with a stricter definition of renal
failure, the greatest benefit of nesiritide infusion was seen in
patients with preexisting moderate to severe renal dysfunc-
tion. In this high-risk population, reducing the risk of post-
operative renal dysfunction may have contributed to the
shorter hospital stay and reduced mortality observed with
nesiritide treatment.4
There are several limitations to this report. This analysis
was a post hoc evaluation of the NAPA trial and thus not
prospectively powered to evaluate the effect of nesiritide
on postoperative renal dysfunction in patients with preex-
isting renal disease. The use of estimated GFR in this anal-
ysis, however, is a more appropriate definition of renal
failure than is change in serum creatinine alone. We con-
sider the data suggesting that nesiritide may be renally
protective in this high-risk population to be provocative.
Further evaluation of the perioperative use of nesiritide
to prevent renal dysfunction after cardiac surgery is
warranted.
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